Related Experiment Videos
Endobronchial treatment modalities in thoracic oncology
1Department of Chest Oncology, The Netherlands Cancer Institute, Amsterdam.
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise study.
ESMO real world data and digital oncology·2026
Development of a history-taking form for mesothelioma patients at risk of exposure to asbestos.
Public health action·2025
Properties of CD8 T-cell-recognized neoantigens in different tumor types.
Immuno-oncology technology·2025
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
Lung cancer (Amsterdam, Netherlands)·2024
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Annals of oncology : official journal of the European Society for Medical Oncology·2022
Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
A multimodal deep learning model for preoperative prediction of post-operative complications in gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026